<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765423</url>
  </required_header>
  <id_info>
    <org_study_id>CASE11820</org_study_id>
    <nct_id>NCT04765423</nct_id>
  </id_info>
  <brief_title>Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease</brief_title>
  <official_title>[F-18] Fluciclovine (Axumin) PET/CT vs. [F-18] NaF PET/CT in the Evaluation of Prostate Cancer Osseous Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at whether F-18 Fluciclovine (i.e. Axumin) is better or&#xD;
      as good as F-18 Sodium Fluoride (F-18 NaF) when looking at bone disease from prostate cancer.&#xD;
      Axumin is a radioactive agent used on a positron/computed tomography (PET/CT) camera to look&#xD;
      for prostate cancer in general.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess the diagnostic performance of [F-18] fluciclovine PET/CT compared to&#xD;
      [F-18] NaF PET/CT as the reference standard. Each bone lesion identified on [F-18] NaF PET/CT&#xD;
      will be compared with the level of [F-18] fluciclovine uptake&#xD;
&#xD;
      The primary objective is to assess [F-18] fluciclovine efficacy in the evaluation of osseous&#xD;
      metastatic disease in prostate cancer on a lesion-by-lesion comparison with [F-18] NaF as a&#xD;
      the reference standard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of lesions seen by [F-18] NaF PET/CT which are also seen by [F-18] fluciclovine PET/CT</measure>
    <time_frame>At time of scan, up to 60 minutes per scan</time_frame>
    <description>Agreement of imaging methods as measured by number of lesions seen by [F-18] NaF PET/CT which are also seen by [F-18] fluciclovine PET/CT broken down by diagnostic score on a lesion-by-lesion basis (1 to 5)&#xD;
Definitely benign&#xD;
Probably benign&#xD;
Equivocal&#xD;
Probably malignant&#xD;
Definitely malignant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>At time of scan, up to 60 minutes per scan</time_frame>
    <description>Accuracy of [F-18] fluciclovine PET/CT compared to [F-18] NaF PET/CT evaluated via sensitivity&#xD;
Sensitivity is the number of true positives (TP) divided by the sum of TP and false negatives (FN):&#xD;
Sensitivity = TP / (TP+FN)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>At time of scan, up to 60 minutes per scan</time_frame>
    <description>Accuracy of [F-18] fluciclovine PET/CT compared to [F-18] NaF PET/CT evaluated via specificity&#xD;
Specificity is the number of true Negatives (TN) divided by the sum of TN and false positives (FP):&#xD;
Sensitivity = TN / (TN+FP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Predictive Value (PPV)</measure>
    <time_frame>At time of scan, up to 60 minutes per scan</time_frame>
    <description>Accuracy of [F-18] fluciclovine PET/CT compared to [F-18] NaF PET/CT evaluated via PPV&#xD;
PPV is the number of true TP divided by the sum of TP and FP:&#xD;
Sensitivity = TP / (TP+FP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Predictive Value (NPV)</measure>
    <time_frame>At time of scan, up to 60 minutes per scan</time_frame>
    <description>Accuracy of [F-18] fluciclovine PET/CT compared to [F-18] NaF PET/CT evaluated via NPV&#xD;
NPV is the number of true TN divided by the sum of TN and FN:&#xD;
Sensitivity = TN / (TN+FN)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>At time of scan, up to 60 minutes per scan</time_frame>
    <description>Accuracy of [F-18] fluciclovine PET/CT compared to [F-18] NaF PET/CT evaluated via AUC using Receiver Operating Characteristic (ROC) curves</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malignant Neoplasm of Prostate</condition>
  <arm_group>
    <arm_group_label>NaF PET/CT scan and F-18 fluciclovine PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visit 1: Participant receives a whole body [F-18] NaF PET/CT (diagnostic study)&#xD;
Visit 2: Participant receives a whole body [F-18] fluciclovine PET/CT within 3 weeks of Visit 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>[F-18] NaF PET/CT</intervention_name>
    <description>Radiotracer F-18 NaF used on the PET/CT imaging</description>
    <arm_group_label>NaF PET/CT scan and F-18 fluciclovine PET/CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>[F-18] fluciclovine PET/CT</intervention_name>
    <description>F-18 fluciclovine (Axumin Â®) used on the PET/CT camera</description>
    <arm_group_label>NaF PET/CT scan and F-18 fluciclovine PET/CT</arm_group_label>
    <other_name>Axumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Referred for initial staging or restaging of prostate cancers with clinical suspicion&#xD;
             of bone metastases.&#xD;
&#xD;
          -  Must understand and voluntarily sign an Informed Consent Document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Cannot tolerate imaging up to 60 minutes of total imaging&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Jones, MD</last_name>
    <phone>1-800-641-2422</phone>
    <email>CTUReferral@UHhospitals.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Jones, MD</last_name>
      <phone>800-641-2422</phone>
      <email>CTUReferral@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Robert Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No current plans to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

